02.2Healthcare & Medical
Pharma & biotech
In pharma and biotech the science is only half the risk; the other half is capital strategy, portfolio choices, and a commercial launch that has to land in a narrow window. The bets are long, expensive, and unforgiving.
The terrain
What decides outcomes in this sector
Drug development is a long-odds, capital-intensive business where a single portfolio or launch decision can define a company. The timelines dwarf almost every other industry, the regulatory and evidence requirements are absolute, and the commercial value is concentrated into launch and lifecycle windows that reward preparation and punish improvisation.
We work above the science, on the business decisions that surround it: portfolio and capital strategy, commercial and launch planning, and the operating model that turns a pipeline into a business. A patent clock that runs just 20 years from filing, with a chunk of that already spent by launch, is what makes every timeline decision in this sector a capital decision. Our founder's prior work was in M&A, valuation, and capital strategy, which is squarely the analytical rigor this sector's biggest decisions demand.
- Practice
- Healthcare & Medical
- Taxonomy
- 02.2
- Reach
- Worldwide
The hard calls
The decisions that carry the most weight
Pick the call in front of you. Each pairs with the services our practice maps to this sector: real pages, real scope, no packaged pitch.
01Portfolio and capital allocation
With finite capital and long timelines, which programs to fund and which to cut is the defining decision. We bring valuation and scenario rigor to the portfolio calls that shape the company.
Where we start on calls like this
The services our practice maps to this sector.
- Executive financial advisoryPortfolio, capital-allocation, and M&A decisions that carry transaction-grade stakes.
- Strategy consultingCommercial, access, and launch strategy in a value-concentrated window.
- Innovation consultingBuild and validate new therapeutic or commercial models before betting the capital.
- Compliance consultingFrameworks for a sector where regulatory rigor is absolute and non-negotiable.
02Commercial launch in a narrow window
Value concentrates into a launch that has to execute. We help build the commercial and launch strategy (access, positioning, and readiness) before the window opens, not during it.
Where we start on calls like this
The services our practice maps to this sector.
- Executive financial advisoryPortfolio, capital-allocation, and M&A decisions that carry transaction-grade stakes.
- Strategy consultingCommercial, access, and launch strategy in a value-concentrated window.
- Innovation consultingBuild and validate new therapeutic or commercial models before betting the capital.
- Compliance consultingFrameworks for a sector where regulatory rigor is absolute and non-negotiable.
03Business development and deal strategy
Licensing, partnerships, and M&A are how pipelines get built and de-risked. We bring transaction-grade analysis to what to buy, partner, or license, and on what terms.
Where we start on calls like this
The services our practice maps to this sector.
- Executive financial advisoryPortfolio, capital-allocation, and M&A decisions that carry transaction-grade stakes.
- Strategy consultingCommercial, access, and launch strategy in a value-concentrated window.
- Innovation consultingBuild and validate new therapeutic or commercial models before betting the capital.
- Compliance consultingFrameworks for a sector where regulatory rigor is absolute and non-negotiable.
04AI in discovery: signal versus story
AI-driven discovery is real in places and overstated in others. We help separate where it genuinely changes the economics from where it's a narrative, and invest accordingly.
Where we start on calls like this
The services our practice maps to this sector.
- Executive financial advisoryPortfolio, capital-allocation, and M&A decisions that carry transaction-grade stakes.
- Strategy consultingCommercial, access, and launch strategy in a value-concentrated window.
- Innovation consultingBuild and validate new therapeutic or commercial models before betting the capital.
- Compliance consultingFrameworks for a sector where regulatory rigor is absolute and non-negotiable.
Questions
What should you know about pharma & biotech before you reach out?
- Do you have clinical or regulatory affairs expertise?
- No. Those belong to your clinical and regulatory teams. We work on the commercial, portfolio, capital, and deal strategy around the science, where the analytical rigor of our background is the fit.
- Can you help evaluate a licensing or M&A opportunity?
- Yes. Transaction analysis (valuation, structure, and the strategic case) is core strength. We bring the same rigor to a licensing deal or acquisition that the decision's stakes demand, alongside your scientific due diligence.
Adjacent sectors
Related sectors
- 02.3Medical devicesDevice makers where regulation, reimbursement, and the sales channel decide adoption.
- 02.4Digital healthHealth-tech companies proving clinical value and a business model at the same time.
- 02.5Payers & health insurersHealth plans balancing medical cost, member experience, and regulatory pressure.
- 02.1Hospital & health systemsProvider organizations balancing care quality, margin, and system-wide change.
A strategy or operating decision that has to hold under real stakes?
Value-based-care positioning, AI governance, or a transformation that can't break clinical trust. Tell us what you're deciding, and we'll scope it honestly.
No obligation · a scoping conversation first